Clinical Trial

Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study

Study acronym: MACRONAC
Recruiting
View on ClinicalTrials.gov →
Summary
In this multicenter retrospective cohort study the aim is to determine the safety of omission of axillary lymph node dissection in patients with TNBC and HER2+ tumors with residual macrometastases (in the SLN/TAD/TAS or MARI node) after NAC.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Recruiting 2026-05-20
Trial Details
NCT Number NCT07546695
Lead Sponsor University Hospital, Basel, Switzerland
Conditions Breast Cancer
Enrollment 600 participants
Start Date 2026-02-01
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-19